by jtierney | Jan 7, 2026 | Press Releases
U.S. IND represents the second regulatory clearance for KLN-1010 and enables the first multi-center clinical trial in the U.S. for an anti-BCMA in vivo CAR-T program BOSTON,...
by jtierney | Dec 9, 2025 | Press Releases
100% MRD-negative response rate in four patients; all remain in response through the longest follow up of 5 months Favorable toxicity profile with no CRS grade 3 or above and no ICANS Potent CAR-T expansion from a single, an off-the-shelf infusion without...
by jtierney | Nov 24, 2025 | Press Releases
Early results from the Phase 1 inMMyCAR™ study demonstrate ongoing MRD-negative responses in all patients with a tolerable safety profile Robust CAR-T cell expansion occurred in the absence of preparative chemotherapy Persistent, memory CAR-T cells in all...
by jtierney | Nov 5, 2025 | Press Releases
Kelonia Therapeutics, Inc., a clinical-stage biotechnology company pioneering in vivo gene delivery, today announced a strategic collaboration with Johnson & Johnson* to advance the discovery of novel in vivo CAR-T cell therapies. The collaboration aims to develop...